ReviewCardiovascular diabetology. Endocrinology reports2026
Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework.
Review in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Cardiovascular-Kidney-Metabolic (CKM) syndrome framework acknowledges metabolic dysfunction-associated steatotic liver disease (MASLD) as a major manifestation, yet hepatic involvement remains insufficiently incorporated into risk stratification. This review proposes the metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome as an operational extension that integrates hepatic fibrosis assessment into cardiometabolic-renal care.
methodsWe conducted a comprehensive narrative review across PubMed/MEDLINE, Embase, Web of Science, Cochrane Library, and Scopus through March 2026. We synthesized evidence on pathophysiological crosstalk, proposed the Multi-Organ Risk Score (MORS)-enabled MMCK staging criteria (Stages 0-4), and developed stage-specific management algorithms.
resultsThe MMCK framework introduces four key operational advances: (i) quantitative multi-organ risk stratification through the MORS (L + C + B + K, range 0-12) with mandatory FIB-4/VCTE-based hepatic fibrosis assessment as the L-Score; (ii) stage-specific therapeutic thresholds linked to objective clinical cutoffs; (iii) a structured multidisciplinary team governance model with MORS-based electronic health record triggers; and (iv) a three-tiered endpoint framework for quality improvement and prospective validation. Observational evidence indicates that incorporating MASLD fibrosis into cardiometabolic staging improves coronary artery disease risk prediction. The MMCK framework positions MASLD as a cardiovascular risk-modifying axis within established cardiometabolic-renal care.
conclusionsThe MMCK syndrome operationalizes hepatic integration within established cardiometabolic-renal care by providing a quantitative, stage-specific framework for multi-organ risk assessment and management. Future research should prospectively validate MORS-based staging in diverse cohorts and evaluate whether MMCK-guided management improves clinical outcomes compared with CKM-guided care alone.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.